A recent study suggests that people who stop using new GLP-1 drugs like semaglutide or tirzepatide may regain lost weight far faster than those who end conventional diet and exercise regimens.
Findings released in a leading medical journal demonstrates that while overweight individuals often shed about a fifth of their body weight while using the jabs, the weight is regained at an estimated rate of 0.8 kg per month once they quit.
"People using these medications should be cognizant of the risk of rapid rebound weight gain when the treatment is stopped," stated expert Dr. Susan Jebb.
Such speed of regain means a return to original mass in about a year and a half.
Weighing Therapies
The analysis, which reviewed 37 of trials involving over 9,000 of participants, compared the outcomes of the injectable medications with older methods.
Researchers emphasize that people who lose weight through lifestyle changes alone usually experience a slower creep back—perhaps 100 grams monthly—once they finish.
The Reason for the Fast Regain
Nutrition scientists propose the mode of action of the injections explains the heightened rebound.
GLP-1 drugs mimic a body's own chemical called glucagon-like peptide-1, which moderates appetite.
"Artificially providing the hormone concentrations far above than the body's typical production could lead to the body to generate a reduced amount of its endogenous hormone, and could diminish responsiveness to its actions," explained Dr. Adam Collins, a nutrition expert.
"Discontinuation of this medication means hunger is uncontrolled, making overeating much more probable."
A Chronic Condition?
Health authorities advise the jabs for people with weight-linked health risks, accompanied by recommended lifestyle changes.
Many experts contend that, given the likelihood of weight regain, the therapy might need to be long-term.
This view is echoed by drug manufacturers, who state that the findings "highlight the long-term character of obesity," similar to managing diseases like high blood pressure.
Patient Experiences
Users who have come off the jabs report a sudden resurgence of cravings.
"It was like something flipping and you're instantly starving," said an individual.
This challenge is exacerbated if users have not established lasting dietary or behavioural modifications during therapy.
Significant Use
Recent estimates suggest that a significant number of adults in the UK have used these injections in the last 12 months, with desire remaining high.
- Adoption is greater among females compared to men.
- The 40s and 50s age group shows the highest level of interest.
- A large proportion access the drugs through private healthcare rather than the NHS.
In conclusion, researchers stress that while GLP-1 drugs are powerful agents for weight loss, they are not a standalone fix and long-term success hinges on integrated lifestyle management.